Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
Chia‐Ling Yu, Chih‐Sung Liang, Fu‐Chi Yang, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 938-938
Open Access | Times Cited: 25

Showing 25 citing articles:

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 21
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 2
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 649-659
Open Access | Times Cited: 20
A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression
Meghan Hibicke, Hannah M. Kramer, Charles D. Nichols
Psychedelic Medicine (2023) Vol. 1, Iss. 1, pp. 54-67
Closed Access | Times Cited: 15
Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials
Shuping Fang, Xin Yang, Wei Zhang
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Psilocybin for clinical indications: A scoping review
Kim Madden, Breanne Flood, Darren Young Shing, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 10, pp. 839-845
Open Access | Times Cited: 5
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis
Otto Simonsson, Per Carlbring, Robin Carhart‐Harris, et al.
Psychiatry Research (2023) Vol. 327, pp. 115349-115349
Open Access | Times Cited: 11
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 10, pp. 1131-1146
Closed Access | Times Cited: 17
Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists
Emil Märcher-Rørsted, Anders A. Jensen, Gints Šmits, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7224-7244
Open Access | Times Cited: 3
Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials
G. Salvetti, Daniele Saccenti, Andrea Stefano Moro, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 829-829
Open Access | Times Cited: 2
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Aleksandra Barstowe, Petri Kajonius
Journal of Psychoactive Drugs (2024), pp. 1-11
Open Access | Times Cited: 2
Unresolved Systemic Inflammation, Long COVID, and the Common Pathomechanisms of Somatic and Psychiatric Comorbidity
Chih‐Sung Liang, Piotr Gałecki, Kuan‐Pin Su
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 5114-5114
Open Access | Times Cited: 12
Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
José Carlos Bouso, Dóra Révész, Genís Oña, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use
Kiffer G. Card, Ashmita Grewal, Kalysha Closson, et al.
Journal of Psychoactive Drugs (2023), pp. 1-11
Closed Access | Times Cited: 4
Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis
Vikas Menon, Parthasarathy Ramamurthy, Sandesh Venu, et al.
Acta Psychiatrica Scandinavica (2024)
Closed Access | Times Cited: 1
A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
Jennifer Bennett, Michael D. Blough, Ian Mitchell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data
Bheatrix Bienemann, Amanda Rocha Barbosa, Lucas Villar Magalhães da Cruz, et al.
Journal of Psychoactive Drugs (2023) Vol. 56, Iss. 3, pp. 324-332
Open Access | Times Cited: 3
Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats
Natalia Malikowska‐Racia, Maciej Koniewski, Joanna Gołębiowska, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 11, pp. 1149-1156
Closed Access | Times Cited: 3
Sex-Dependent Skin Aging and Rejuvenation Strategies
Marta Gerasymchuk, Gregory Ian Robinson, Nataliia Vardinska, et al.
Dermato (2023) Vol. 3, Iss. 3, pp. 196-223
Open Access | Times Cited: 2
A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder
Raúl Escamilla, María Eva González-Trujano, Jesús M. González Mariscal, et al.
Journal of Psychoactive Drugs (2023) Vol. 55, Iss. 5, pp. 570-580
Closed Access | Times Cited: 2
Masking influences: A systematic review of placebo control and blinding in psychedelic studies
Aleksandra Barstowe, Petri Kajonius
Research Square (Research Square) (2024)
Open Access
Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner
M. Nikolič, Pedro A. M. Mediano, Tom Froese, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Psilocybin-assisted psychotherapy for cancer-related anxiety and depression
Dan Yaniv, Lois M. Ramondetta, Lorenzo Cohen, et al.
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 8, pp. 1327-1328
Closed Access
Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?
Julien Chupin, Jorge López‐Castromán, Caroline Brière, et al.
Medical Hypotheses (2023) Vol. 179, pp. 111163-111163
Open Access
Neuropsychological Effects of Antidepressants: Translational Studies
Katie Kamenish, Emma Robinson
Current topics in behavioral neurosciences (2023), pp. 101-130
Closed Access
Page 1

Scroll to top